The 2.8 Å Electron Microscopy Structure of Adeno-Associated Virus-DJ Bound by a Heparanoid Pentasaccharide
Author
Xie, Q.; Spear, J.; Noble, A.; Sousa, D.; Meyer, N.; Davulcu, O.; Zhang, F.; Stagg, S.; Chapman, M.
Other Contributors
Date Issued
2017Subject
Biology; Chemistry and chemical biology; Chemical and biological engineering; Biomedical engineeringDegree
Terms of Use
CC BY-NC-ND : this license allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.; Attribution-NonCommercial-NoDerivs 3.0 United StatesFull Citation
The 2.8 Å Electron Microscopy Structure of Adeno-Associated Virus-DJ Bound by a Heparanoid Pentasaccharide Q. Xie, J. Spear, A. Noble, D. Sousa, N. Meyer, O. Davulcu, F. Zhang, R. Linhardt, S. Stagg, M. Chapman, Molecular Therapy - Methods & Clinical Development, 5, 1-12, 2017.Metadata
Show full item recordAbstract
Atomic structures of adeno-associated virus (AAV)-DJ, alone and in complex with fondaparinux, have been determined by cryoelectron microscopy at 3 Å resolution. The gene therapy vector, AAV-DJ, is a hybrid of natural serotypes that was previously derived by directed evolution, selecting for hepatocyte entry and resistance to neutralization by human serum. The structure of AAV-DJ differs from that of parental serotypes in two regions where neutralizing antibodies bind, so immune escape appears to have been the primary driver of AAV-DJ's directed evolution. Fondaparinux is an analog of cell surface heparan sulfate to which several AAVs bind during entry. Fondaparinux interacts with viral arginines at a known heparin binding site, without the large conformational changes whose presence was controversial in low-resolution imaging of AAV2-heparin complexes. The glycan density suggests multi-modal binding that could accommodate sequence variation and multivalent binding along a glycan polymer, consistent with a role in attachment, prior to more specific interactions with a receptor protein mediating entry.;Description
Molecular Therapy - Methods & Clinical Development, 5, 1-12; Note : if this item contains full text it may be a preprint, author manuscript, or a Gold OA copy that permits redistribution with a license such as CC BY. The final version is available through the publisher’s platform.Department
The Linhardt Research Labs.; The Shirley Ann Jackson, Ph.D. Center for Biotechnology and Interdisciplinary Studies (CBIS);Publisher
ElsevierRelationships
The Linhardt Research Labs Online Collection; Rensselaer Polytechnic Institute, Troy, NY; https://harc.rpi.edu/;Access
CC BY — Creative Commons Attribution-NonCommercial-NoDerivatives; A full text version is available in DSpace@RPI; Open Access;Collections
The following license files are associated with this item: